CD33 and cystic fibrosis: As compared to the “classical” CD16high/CD62Lhigh (1) subset, the CD16high/CD62Llow (2) subset from stable CF group was more mature (increased CD10 and decreased CD33), less activated (decreased CD11b and CD66b) and showed an altered immunomodulation markers expression (increased PD1 and decreased PD-L1).